Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
17 Mar 2015 07:00 AM
RNS
Issue of equity to Cancer Research Technology Ltd
06 Mar 2015 07:00 AM
RNS
Placing to raise GBP800,000
26 Feb 2015 07:00 AM
RNS
New Endometriosis Patent Grant
24 Feb 2015 07:00 AM
RNS
Successful 1st Results from VAL201 Clinical Trial
11 Feb 2015 07:00 AM
RNS
New European Patent Grant
05 Feb 2015 07:00 AM
RNS
Acquisition
15 Jan 2015 07:00 AM
RNS
Clinical Trial and Development Update
18 Dec 2014 07:00 AM
RNS
Issue of Equity
04 Dec 2014 07:00 AM
RNS
ValiSeek Scientific Update
26 Nov 2014 07:00 AM
RNS
Re: Progress with Trial Recruitment and Testing
13 Nov 2014 07:00 AM
RNS
Collaboration Agreement
07 Nov 2014 10:23 AM
RNS
Holding(s) in Company
03 Nov 2014 11:00 AM
RNS
Approved Clinical Trial Update
31 Oct 2014 07:00 AM
RNS
Total Voting Rights
23 Oct 2014 10:45 AM
RNS
Grant of options
14 Oct 2014 07:00 AM
RNS
Approved Clinical Trial Update
08 Oct 2014 04:12 PM
RNS
Early Completion of Equity Swap Agreement
08 Oct 2014 04:08 PM
RNS
Holding(s) in Company
02 Sep 2014 07:00 AM
RNS
ValiSeek Development Update
28 Aug 2014 11:33 AM
RNS
Holding(s) in Company
19 Aug 2014 07:00 AM
RNS
Half Yearly Report
05 Aug 2014 12:05 PM
RNS
Holding(s) in Company
04 Aug 2014 07:00 AM
RNS
Notice of Acceptance of CTA Request
01 Jul 2014 11:35 AM
RNS
Holding(s) in Company
24 Jun 2014 07:00 AM
RNS
Director/PDMR Shareholding
18 Jun 2014 09:22 AM
RNS
New Corporate Website & New Office Address
10 Jun 2014 07:00 AM
RNS
Submission of Clinical Trial Application re VAL201
15 May 2014 07:00 AM
RNS
ValiSeek Development Update
01 May 2014 07:00 AM
RNS
New Japanese Patent Grant
23 Apr 2014 04:29 PM
RNS
Result of AGM
17 Apr 2014 05:51 PM
RNS
Holding(s) in Company
08 Apr 2014 07:00 AM
RNS
ValiSeek Joint Venture
01 Apr 2014 07:00 AM
RNS
VAL201 Update
31 Mar 2014 04:45 PM
RNS
Notice of AGM
31 Mar 2014 04:09 PM
RNS
Holding(s) in Company
28 Mar 2014 07:01 AM
RNS
Posting of R&As and Notice of AGM
19 Mar 2014 07:00 AM
RNS
Final Results
20 Feb 2014 07:00 AM
RNS
New European Patent Grant
31 Jan 2014 12:45 PM
RNS
Sale of shares in VolitionRx
22 Jan 2014 03:00 PM
RNS
Grant of Options
16 Jan 2014 07:00 AM
RNS
Issue of Equity
27 Dec 2013 07:00 AM
RNS
Fundraising and Equity Swap
05 Dec 2013 07:00 AM
RNS
New Australian Patent Grant
28 Nov 2013 07:00 AM
RNS
Update re Positive VAL201 & Biomarker Unit Studies
15 Nov 2013 07:00 AM
RNS
Placing to raise ?1m
01 Nov 2013 07:00 AM
RNS
Change of Broker
24 Oct 2013 04:25 PM
RNS
Re: VAL201 - Update
08 Oct 2013 07:00 AM
RNS
Directorate Changes
03 Oct 2013 07:00 AM
RNS
Re: VAL201 - Filing of Phase IB Clinical Trial
05 Sep 2013 07:00 AM
RNS
Half Yearly Report

ValiRx PLC: A Biotech Innovator on the London Stock Exchange (LSE)

ValiRx PLC, known by its ticker symbol VAL, is a trailblazer in the biotechnology sector. Its performance on the London Stock Exchange (LSE) has been remarkable, with the ValiRx share price reflecting the company's consistent growth and success.

As a member of the LSE, ValiRx PLC aligns with the London Stock Exchange Group's (LSEG) mission of supporting innovative and growing businesses. The LSEG recognises ValiRx PLC as a significant player, contributing to the robust and diverse ecosystem of the LSE.

The ValiRx share price on the LSE not only underscores its financial stability but also its strategic vision in the biotechnology industry. ValiRx PLC's journey on the LSE is a testament to its robust business model and its ability to create value for its stakeholders.

In conclusion, ValiRx PLC's association with the LSE and LSEG symbolises its commitment to growth, innovation, and value creation. As ValiRx PLC continues to thrive on the LSE, it sets the bar high for the biotechnology industry, contributing to the dynamic and diverse ecosystem of the LSEG. With its focus on cancer therapeutics, ValiRx is a key player in the healthcare sector, making strides in medical research and development.

UK 100

Latest directors dealings